FOXP3 and type 1 diabetes mellitus: This may explain why antigen-specific immunotherapy is proven to be ineffective when administered following T1D onset, as the cognate naïve CD4+ T cell pool diminishes throughout the course of disease, limiting the amount of FoxP3+ Tregs that can be induced.